PerkinElmer to Serve as Exclusive Global Distributor for Sebia’s Hemoglobin Newborn Screening System

Expands Extensive Neonatal Testing Menu to Include Fully Automated Hemoglobin Platform for Immediate Detection and Diagnosis of Inherited Genetic Conditions

PerkinElmer Inc., a global leader focused on the health and safety of people and the environment, today announced an agreement to become the exclusive global distributor for Sebia CAPILLARYS 2 NEONAT FAST offering to newborn screening laboratories. This system enables fully automated hemoglobin newborn screening from dried blood spot samples by capillary electrophoresis.

This year, more than 10 million babies will be screened at birth for several hemoglobinopathies (inherited genetic conditions affecting the number or shape of red blood cells), including sickle cell disease. Detecting this disease through newborn screening can better enable immediate delivery of vaccinations and treatments with antibiotics to prevent infections. 

“As a global leader in newborn screening for more than 25 years, we continue to  expand our innovative panel of testing options, particularly as automation becomes more important to our customers,” said Prahlad Singh, President, Diagnostics, PerkinElmer. “Sebia’s offering complements our extensive portfolio by providing laboratories with an automated hemoglobinopathy screening solution which can help them obtain clinically actionable information and insights to achieve better outcomes.”

“We are pleased to collaborate with PerkinElmer and leverage its global footprint and market leadership in newborn screening to provide greater access to our hemoglobin screening capabilities, helping laboratory professionals to detect life threatening diseases.” said Benoit Adelus, CEO and Chairman for Sebia.

Sebia’s hemoglobin newborn screening assay is designed to separate normal hemoglobins and detect hemoglobin variants.

The CAPILLARYS 2 NEONAT FAST capillary electrophoresis system provides high resolution separation and complete walk-away automation from hemolysate preparation to final color-coded results.

For more information, please visit


About PerkinElmer, Inc.

PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The Company reported revenue of approximately $2.2 billion in 2013, has about 7,600 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index.

Additional information is available through 1-877-PKI-NYSE, or at